• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, March 31, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Bioengineer by Bioengineer
June 15, 2022
in Cancer
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The antibodies were effective against all SARS-CoV-2 variants of concern tested and could be used alone or in an antibody cocktail to diminish the risk of infection.

The Cv2.1169 antibody binds to the SARS-CoV-2 spike protein

Credit: ©2022 Planchais et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20220638

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The antibodies were effective against all SARS-CoV-2 variants of concern tested and could be used alone or in an antibody cocktail to diminish the risk of infection.

Researchers from the Institut Pasteur, Université Paris Cité, and INSERM examined 102 SARS-CoV-2 spike monoclonal antibodies cloned from the B cells of 10 COVID-19 convalescents. They found that the antibodies Cv2.1169 and Cv2.3194 were the only ones to neutralize all SARS-CoV-2 variants, including Omicron BA.1 and BA.2 subtypes. The two antibodies also were fully active against Alpha, Beta, Gamma, and Delta variants. A modified version of the Cv2.1169 antibody was also effective at treating SARS-CoV-2 infection in mice and hamsters.

“The broadly neutralizing antibodies we described were more efficient in vitro than many anti–SARS-CoV-2 monoclonals previously approved by the FDA for treatment or prevention. Therefore, we are pretty confident that they represent premium candidates for pre-exposure prophylaxis in immunocompromised patients,” says Hugo Mouquet, head of the Laboratory of Humoral Immunology at the Institut Pasteur, who led the study.

Previous research has shown that SARS-CoV-2 spike-specific monoclonal antibodies play a key role in providing in vivo protection and have been used in developing COVID-19 vaccines. However, immunocompromised individuals still lack effective immunity against SARS-CoV-2 infection.

“A key point is that those monoclonals have been engineered for extending their half-lives and therefore have an expected prolonged effect in people but would still require regular injections, possibly every few months, to maintain protective antibody titers,” Mouquet says. The first molecule being developed based on the new research, SPK001, is being studied by the biotech company SpikImm, and clinical trials are expected to start in the middle of this year.

The research has its roots in a task force launched by the Institut Pasteur in the early days of the COVID-19 pandemic. The Mouquet lab focused its efforts on immunotherapeutics because of its ongoing study of human antiviral monoclonal antibodies, including molecules of prophylactic and/or therapeutic potential against HBV and HIV-1.

Notably, one of the two broadly neutralizing antibodies, Cv2.1169, is a type of antibody known as immunoglobulin A that is produced by B cells in the body’s mucosal tissues, such as the respiratory tract, and can be crucial in the early response to respiratory pathogens like SARS-CoV-2.  

“One aspect of our work highlights the role of IgA antibodies for a broad SARS-CoV-2 neutralization. When studying immune responses against pathogens affecting mucosal tissues, we thus consider that IgA-mediated antibody response should be systematically investigated, including in the quest of isolating broadly neutralizing monoclonal antibodies,” Mouquet says.

 

Planchais et al. 2022. J. Exp. Med. https://rupress.org/jem/article-lookup/doi/10.1084/jem.20220638?PR

 

# # #

About Journal of Experimental Medicine

Journal of Experimental Medicine (JEM) publishes peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Established in 1896, JEM is published by Rockefeller University Press, a department of The Rockefeller University in New York. For more information, visit jem.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JEM on Twitter at @JExpMed and @RockUPress.



Journal

Journal of Experimental Medicine

DOI

10.1084/jem.20220638

Method of Research

Experimental study

Subject of Research

Animals

Article Title

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

Article Publication Date

15-Jun-2022

COI Statement

C. Planchais reported a patent to PCT/EP2022/
058777 licensed (SpikImm). I. Fern´andez reported a patent to
PCT/EP2022/058777 licensed (SpikImm). T. Bruel reported a
patent to PCT/EP2022/058777 licensed (SpikImm). G.D. deMelo
reported a patent to PCT/EP2022/058777 licensed (SpikImm). P.
Charneau reported personal fees from TheraVectys outside the
submitted work; in addition, P. Charneau had a patent for seroneutralization
pending. S. van der Werf reported a patent for
the use of proteins and peptides coded by the genome of a novel
strain of SARS-associated coronavirus issued and a patent for SARS-associated coronavirus diagnostics issued. H. Bourhy reported
a patent to PCT/EP2022/058777 licensed (SpikImm) and a
patent to PCT/IB2021/000314 issued. X. Montagutelli reported a
patent to PCT/EP2022/058777 licensed (SpikImm). F.A. Rey reported
a patent to PCT/EP2022/058777 licensed (SpikImm). O.
Schwartz reported a patent to PCT/EP2022/058777 licensed
(SpikImm). H. Mouquet reported grants from SpikImm and
personal fees from SpikImm during the conduct of the study; in
addition, H. Mouquet had a patent to PCT/EP2022/058777 licensed
(SpikImm). No other disclosures were reported.

Share12Tweet8Share2ShareShareShare2

Related Posts

Figure 7

Metformin & leucine prevent cellular senescence & proteostasis disruption

March 31, 2023
blood brain barrier

New study offers clues to how cancer spreads to the brain

March 31, 2023

Oregon State researchers develop new model for quickly evaluating potential cervical cancer drugs

March 31, 2023

Researchers report that the outcome of patients with a rare type of astrocytoma, a neuron tumor, is worse than expected

March 31, 2023

POPULAR NEWS

  • ChatPandaGPT

    Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform

    68 shares
    Share 27 Tweet 17
  • Extinction of steam locomotives derails assumptions about biological evolution

    49 shares
    Share 20 Tweet 12
  • Northern and southern resident orcas hunt differently, which may help explain the decline of southern orcas

    44 shares
    Share 18 Tweet 11
  • Skipping breakfast may compromise the immune system

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cookin’ with gas: UWO professor earns patent for flameless industrial oven

After spinal cord injury, kinesthetic sense helps restore movement, model suggests

Plastic transistor amplifies biochemical sensing signal

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 48 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In